Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SToP-CAV: Statin Intensity to Prevent CAV
NCT05251129Withdrawn
- Sponsor
- Montefiore Medical Center
- Start
- Jan 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of atorvastatin in Cardiac allograft vasculopathy (CAV) (2 arms), sponsored by Montefiore Medical Center. Primary endpoint: Myocardial Flow Reserve at 2 years. Planned start Jan 2025; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
Cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT05251129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251129.